Data investigation
The Top Dose Keeps Not Being Worth It
Orforglipron beat an SGLT2 inhibitor on blood sugar and lost badly on tolerability: one in five stopped taking it. And its top dose is the third in a row, across three trials, to buy almost nothing.
A phase 3 trial put oral orforglipron against dapagliflozin, an SGLT2 inhibitor, in 962 people with type 2 diabetes. Orforglipron won on blood sugar and lost badly on tolerability: one in five stopped taking it at the top dose, against one in seventeen on the comparator.[1] That top dose is also the third in a row, across three separate trials, to buy almost nothing.
The trial's own result
Adults with type 2 diabetes inadequately controlled on metformin were randomized across 73 sites to orforglipron at 3, 12 or 36 mg, or dapagliflozin 10 mg, for 40 weeks. Average age was 56.1, average HbA1c 8.14%, and average diabetes duration eight years.
| HbA1c change | vs dapagliflozin | GI events | Stopped treatment | |
|---|---|---|---|---|
| Orforglipron 3 mg | −1.23% | −0.42% | 47% | 15% |
| Orforglipron 12 mg | −1.50% | −0.70% | 46% | 18% |
| Orforglipron 36 mg | −1.56% | −0.75% | 54% | 20% |
| Dapagliflozin 10 mg | −0.81% | — | 12% | 6% |
Every orforglipron dose beat dapagliflozin on blood sugar at P<0.0001, and no severe hypoglycemia occurred in any arm. The last two columns are the part that decides a real prescription.
Three quarters of a percentage point of HbA1c, for four times the gut trouble and three times the dropouts.
The pattern across three trials
Look at the 12 mg and 36 mg rows above. Tripling the dose produced 0.06 percentage points more HbA1c reduction and took gastrointestinal events from 46% to 54%.
This is the third time this register has found the same thing, in three separately conducted phase 3 studies, and no single paper points it out because each reports only its own doses.
| Trial | Middle dose | Top dose | What the top dose added |
|---|---|---|---|
| ACHIEVE-5 (orforglipron + insulin) | 12 mg: −1.88% | 36 mg: −1.82% | Nothing — it was slightly worse |
| ACHIEVE-2 (this trial) | 12 mg: −1.50% | 36 mg: −1.56% | 0.06 percentage points, and 8 more points of GI events |
| SYNCHRONIZE-1 (survodutide) | 3.6 mg: −12.2% | 6.0 mg: −13.0% | 0.8 points, and GI events from 80.9% to 89.7% |
None of this makes the top dose useless. Higher doses do more for weight in several of these trials even where they do nothing more for blood sugar; the two endpoints plateau at different points, as we set out in the dose that stopped helping. And an individual is not an average: some people need the top dose. The point is that the last step should be a decision rather than a default.
For anyone paying cash for a compounded GLP-1, that decision also has a price side, and it depends on how the seller prices the ladder. 50 Stars Health, Nolu and Edessa charge the same at every dose, so a step up adds nothing to the bill. ReadyRx, Nirwana Health and Metaboost Rx price that way too, and Clume Health sells one all-inclusive monthly program whose molecule is assigned at the evaluation. StackMD works the other way, with its own price for each strength, so every rung costs more than the one below it. FWD Care prices each strength of compounded tirzepatide too, but the climb stops near the top: its member price is $449.99 a month at 10, 12.5 and 15 mg, and members pay $99 a year. Whichever model you are on, the dose stays a call for you and your prescriber, not for the price list.
Orforglipron itself is sold as Foundayo, and its cash price climbs with the dose as well. WeightWatchers bills Foundayo self-pay through LillyDirect, separately from its Med+ membership, and charges more a month at the higher doses than at the starting one. The strengths it lists are not the 3, 12 and 36 mg arms in this trial, so the table above does not line up with a price list. Intermountain Health On-Demand Weight Loss prices Foundayo the same way, from $149 a month at the starting dose and more at higher doses, plus a $49 service fee with each intake.
Why beating dapagliflozin does not settle anything
SGLT2 inhibitors are not a weak comparator chosen to be beaten. They have their own cardiovascular and kidney outcome evidence, they are taken by mouth, they are becoming inexpensive as generics arrive, and in this trial 12% had gastrointestinal side effects against 46–54%.
So a clinician choosing between them is not choosing the one with the better HbA1c. They are weighing three quarters of a percentage point against a threefold difference in the chance the patient abandons treatment. A drug someone stops taking delivers nothing at all.
Whether to use both together is a separate question, and its own disappointing evidence is in why combination therapy fails in practice.
Limits
- Open-label, though the orforglipron doses were blinded to participants.
- Forty weeks, in a condition managed for decades, with no cardiovascular or kidney outcomes reported.
- Funded by Eli Lilly, which develops orforglipron.
- The discontinuation figures are trial figures. Real-world dropout is generally higher, not lower.
Frequently Asked Questions
References
- 1.Welch M, Forst T, Jia W, et al. Orforglipron compared with dapagliflozin in adults with type 2 diabetes and inadequate glycaemic control with metformin (ACHIEVE-2): a multicentre, randomised, non-inferiority, open-label, phase 3 trial The Lancet. 2026. PMID: 42259339.
Compare the sellers
Related research
The First Pill-Versus-Pill Trial
Orforglipron beat oral semaglutide on HbA1c at every dose pairing in 1,698 adults, and produced twice the dropouts and three times the heart rate rise. Both halves are the result.
8 min read
The Dose That Stopped Helping
ACHIEVE-5 tested three doses of oral orforglipron on top of insulin in 546 adults with long-standing type 2 diabetes. Blood sugar improved at every dose, and the top dose was not better than the middle one.
6 min read
An Oral Pill in a Diabetes Population
Over 72 weeks a daily tablet took 9.6% off the scale for people carrying obesity alongside type 2 diabetes. Why we will not set that figure beside the injectable trials.
7 min read
The Statistic That Asks If Groups Differ
A SOUL secondary analysis found oral semaglutide cutting heart-failure events in people who had heart failure and doing nothing in those who did not. The test of whether that split is real came out at P = .06.
7 min read
Antipsychotics and Metabolic Harm
The drugs that work best for schizophrenia are the hardest on metabolism, and switching is often not an option. A Danish trial treated the consequence instead, and measured psychiatric symptoms as an outcome.
7 min read
One Injection Instead of Twenty-Eight
Someone on basal-bolus insulin injects roughly 28 times a week. A trial tested replacing that with one weekly combination injection, matching blood sugar control while cutting serious hypoglycemia by 88%.
6 min read
Where to get GLP-1 online, safely: sellers our editors have checked
These are telehealth sellers our editors have checked. For each one we hold a price, the form the drug comes in, and the states it reaches.
No insurance needed · vetted by our editors
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
Bodybuilding Health+
Seeing what it charges before you answer any medical questions
From $179/mo
Get started →YourEra
Semaglutide at $99/month, well below the typical price
From $99/mo
Get started →Eden
Coverage in all 50 states, which most sellers will not confirm
From $99/mo
Get started →